ImmuneOncia Therapeutics, Inc. Founded in 2016 as a joint venture between Yuhan and Sorrento, ImmuneOncia combines the expertise of both companies in drug development and antibody engineering. Our mission is to provide safe, effective, and innovative immunotherapies to cancer patients worldwide.

Our diverse portfolio includes a range of immune checkpoint antibodies. We are proud to have received approval for a multi-regional Phase II study of IMC-001 in Korea and China, and we have initiated a Phase I study of IMC-002 in the U. S.

These studies demonstrate our commitment to advancing immuno-oncology treatments. Yuhan Corporation, established in 1926, is a leading healthcare company in South Korea. With a strong presence in primary and specialty care, dietary supplements, and contract manufacturing, Yuhan is a valued partner in our endeavors.

Sorrento, on the other hand, is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and autoimmune diseases. Located in Seongnam-si, Gyeonggi-do, ImmuneOncia is dedicated to advancing immune-based therapies and improving outcomes for cancer patients. Join us in our mission to transform the future of cancer treatment